Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
Full description
The Synovate Study is a global, randomized, double-blind, placebo-controlled, phase 3 study in patients with unresectable, locally-advanced or metastatic New York esophageal squamous cell carcinoma 1 (NY-ESO-1) positive synovial sarcoma following first-line systemic anti-cancer therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Selected Inclusion Criteria:
Selected Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
1 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal